These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37176141)

  • 1. Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata.
    Guan Y; Yan A; Qiang W; Ruan R; Yang C; Ma K; Sun H; Liu M; Zhu H
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata.
    Li Q; Wang Y; Guo Q; Cao J; Feng Y; Ke X
    J Control Release; 2024 Aug; 372():778-794. PubMed ID: 38936744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review - alopecia areata and tofacitinib in paediatric patients.
    Bandeira A; Albino-Teixeira A; Magina S
    Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drugs under investigation for the treatment of alopecias.
    Ocampo-Garza J; Griggs J; Tosti A
    Expert Opin Investig Drugs; 2019 Mar; 28(3):275-284. PubMed ID: 30642204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L; Skopit S
    J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alopecia areata: A multifactorial autoimmune condition.
    Simakou T; Butcher JP; Reid S; Henriquez FL
    J Autoimmun; 2019 Mar; 98():74-85. PubMed ID: 30558963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new strategy for modulating chemotherapy-induced alopecia, using PTH/PTHrP receptor agonist and antagonist.
    Peters EM; Foitzik K; Paus R; Ray S; Holick MF
    J Invest Dermatol; 2001 Aug; 117(2):173-8. PubMed ID: 11511291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
    Asilian A; Mohammadian P; Shahmoradi Z
    J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-level laser treatment accelerated hair regrowth in a rat model of chemotherapy-induced alopecia (CIA).
    Wikramanayake TC; Villasante AC; Mauro LM; Nouri K; Schachner LA; Perez CI; Jimenez JJ
    Lasers Med Sci; 2013 May; 28(3):701-6. PubMed ID: 22696077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
    Benton S; Farah R; Freese R; Hordinsky M
    Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of N-acetylcysteine on hair follicle changes in mouse model of cyclophosphamide-induced alopecia: histological and biochemical study.
    Hassan YF; Shabaan DA
    Histochem Cell Biol; 2024 Jun; 161(6):477-491. PubMed ID: 38641701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical mechlorethamine restores autoimmune-arrested follicular activity in mice with an alopecia areata-like disease by targeting infiltrated lymphocytes.
    Tang L; Cao L; Bernardo O; Chen Y; Sundberg JP; Lui H; Chung S; Shapiro J
    J Invest Dermatol; 2003 Mar; 120(3):400-6. PubMed ID: 12603852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of intrafollicular apoptosis in chemotherapy-induced alopecia by topical calcitriol-analogs.
    Schilli MB; Paus R; Menrad A
    J Invest Dermatol; 1998 Oct; 111(4):598-604. PubMed ID: 9764839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral tofacitinib for the treatment of alopecia areata in pediatric patients.
    Kibbie J; Kines K; Norris D; Dunnick CA
    Pediatr Dermatol; 2022 Jan; 39(1):31-34. PubMed ID: 34779041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.